AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.63
+8.97%Year over year
Reported trailing growth
- Revenue
- -86.6%
- EBITDA
- -67.6%
- EBIT
- -51.9%
- EPS
- —
- Free cash flow
- -40.0%
- Operating cash flow
- -40.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +42.3%
Three-year CAGR
- Revenue
- -85.2%
- EBITDA
- —
- EBIT
- -6.4%
- Net income
- —
- EPS
- -35.2%
- Free cash flow
- -4.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026